Pancreatic Cancer Research

ResearcherUniversity of ArizonaNo recent work listed

Ali McBride

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9430-4675; OpenAlex author ID A5049387929. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper

Papers 9

  1. Conversion to biosimilar pegfilgrastim-cbqv enables budget-neutral access to FOLFIRINOX treatment for metastatic pancreatic cancer. Co-author DOI 10.2217/fon-2021-0718↗
  2. Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis. Co-author DOI 10.1080/14740338.2020.1715939↗
  3. Analyzing outcomes of neoadjuvant and adjuvant treatment for borderline-resectable pancreatic adenocarcinoma in the perioperative period at an academic institu… Co-author DOI 10.21037/apc.2020.02.01↗
  4. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1080/13543784.2019.1632289↗
  5. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal a… Co-author DOI 10.21037/apc.2019.06.01↗
  6. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. First author DOI 10.1007/s40273-018-0678-6↗
  7. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. First author DOI 10.1007/s40273-018-0684-8↗
  8. Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review. Co-author DOI 10.1007/s40273-016-0452-6↗
  9. Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRIN… Co-author DOI 10.1080/17512433.2017.1365598↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ivo L Abraham · 4 shared papers, 2018–2021 · strength 0.48
  2. Hani M. Babiker · 4 shared papers, 2019–2020 · strength 0.43
  3. Alejandro Recio‐Boiles · 3 shared papers, 2019–2020 · strength 0.32
  4. Mahdi Gharaibeh · 3 shared papers, 2017–2018 · strength 0.27
  5. Karen MacDonald · 1 shared paper, 2021 · strength 0.19
  6. Sreenivasa Rao Chandana · 1 shared paper, 2019 · strength 0.11
  7. Daruka Mahadevan · 1 shared paper, 2019 · strength 0.11
  8. Nasser Alkhushaym · 1 shared paper, 2020 · strength 0.11
  9. Mok Oh · 1 shared paper, 2020 · strength 0.11
  10. Aaron James Scott · 1 shared paper, 2020 · strength 0.11
  11. Manish Patel · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.